Bionomics announces Phase 2 clinical trial
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Bionomics Limited (ASX:BNO) has today announced that a Phase 2 clinical trial for BNC210 has commenced in elderly patients with agitation in a hospital setting. The first participant has been recruited into the trial.
The global biopharmaceutical company seeks to evaluate the effect of BNC210 on the resolution of agitation in hospitalised elderly patients and assess the safety and tolerability of BNC210. Results of this clinical trial will be available in the first quarter of 2019.
Agitated behavioural disturbances in elderly patients is a major clinical problem, occurring acutely in hospitalised patients and chronically in nursing home residents.
These agitated behaviours can cause distress for the patient and to other patients, and can interfere with the therapeutic procedures for which the patient is hospitalised.
With no approved treatments for agitation, current options include benzodiazepines and antipsychotics which can have severe adverse effects in elderly patients, including sedation, stroke and sudden death.
The clinical trial will involve approximately 40 elderly patients in specialist geriatric hospital wards across Australia, and is a randomised, double-blind, placebo-controlled design with a five-day treatment period.
Bionomics CEO and Managing Director Dr Deborah Rathjen commented: “Bionomics has entered an important period with the results of two ongoing Phase 2 trials now anticipated near term. Agitation in the elderly, which has an underlying component of anxiety, has significant unmet treatment needs, with only approximately 9% of patients suffering agitation receiving drug treatment.
“The hospitalised or nursing home agitation setting represents a rapid potential path to market for BNC210 and builds on the findings of the successful Phase 2 clinical trials of BNC210 in patients with Generalised Anxiety Disorder (GAD).
“Last month we completed recruitment into our BNC210 Phase 2 clinical trial in patients suffering Post-Traumatic Stress Disorder (PTSD). As previously advised, we anticipate data in 2H, 2018.”
BNO remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
About BNC210
BNC210 is a novel, first-in-class, negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Acetylcholine and the alpha-7 receptor are increasingly being implicated in the symptoms of anxiety and depression. Furthermore, the alpha-7 receptor is highly expressed in the amygdala, which forms part of the emotional centre of the brain.
BNC210 has been shown to be well tolerated and not sedating. Clinical trials have shown effects of BNC210 that are consistent with anti-anxiety action, even after a single administration, indicating a rapid onset of action and potential for therapeutic benefit in agitated elderly patients.
To date, BNC210 has been evaluated in seven completed clinical trials in over 200 subjects. Recruitment has been completed in a Phase 2 PTSD trial with 193 participants.
About Bionomics Limited
Bionomics is a global, clinical stage biopharmaceutical company that leverages its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. The company has a strategic partnership with Merck & Co., Inc (known as MSD outside of the United States and Canada).
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
